PFKFB2 as a Potential Survival Marker in Sinonasal Undifferentiated Carcinoma
Takahashi, Y., et al. PFKFB2 as a Potential Survival Marker in Sinonasal Undifferentiated Carcinoma. J Neuorol Surg B 2019; 80(S01): S1-S244.
- Categories
- Abstracts
Takahashi, Y., et al. PFKFB2 as a Potential Survival Marker in Sinonasal Undifferentiated Carcinoma. J Neuorol Surg B 2019; 80(S01): S1-S244.
Wang, Q., et al. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Turner, N. C., et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 2019 Feb 26; 37:1169-1178
Koshkin, V. S., et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research. 2019 Jan 1; 25(1) 210-221.
Martin-Broto, J., et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2018 Dec. http://dx.doi.org/10.1016/S1470-2045(18)30676-4
Richter, J. et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Poster Presented at: ASH Annual meeting session 626. 2018 Dec 3. San Diego, CA
Download pdf 1.1MB
View External Link
Suda, K. et al., CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Mol Cancer Therapeutics; 17(10) 2077, Oct 2017
Download pdf 1.3MB
View External Link
Sunakawa, Y. et al. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC)patients. Abstract presented at: 2018 Congress European Society for Medical Oncology (ESMO); 2018 Oct 21; Munich, Germany. Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281.
Sunakawa, Y., et al. Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer. Mol Cancer Ther. 2018 Oct 1. pii. molcanther.0694.2018. doi: 10.1158/1535-7163.MCT-18-0694 [Epub ahead of print]
Hendriks, L. E., et al. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Translational Lung Cancer Research 2018: 7(6):647-660
Lopez-Pedrera, C., et al. Circulating mirnas as potential biomarkers of disease and cardiovascular risk in rheumatoid arthritis patients. Annals of the Rheumatic Disease 2018 (77) S2
Page last updated May 22, 2023